冠昊生物
(300238)
| 流通市值：43.75亿 | | | 总市值：43.75亿 |
| 流通股本：2.65亿 | | | 总股本：2.65亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 200,869,647.98 | 94,797,135.39 | 377,483,103.8 | 278,135,520.4 |
| 营业收入 | 200,869,647.98 | 94,797,135.39 | 377,483,103.8 | 278,135,520.4 |
| 二、营业总成本 | 176,257,580.55 | 76,040,276.86 | 334,942,285.38 | 249,921,949.86 |
| 营业成本 | 44,086,491.08 | 21,756,284.1 | 77,525,843.69 | 59,418,347.34 |
| 税金及附加 | 2,983,951.39 | 1,086,779.49 | 5,256,670.06 | 2,856,459.25 |
| 销售费用 | 78,257,549.89 | 31,391,817.06 | 157,460,394.2 | 118,255,574.23 |
| 管理费用 | 30,605,219.15 | 13,010,932.5 | 57,170,350.92 | 40,650,655.56 |
| 研发费用 | 18,507,771.58 | 7,798,700.14 | 36,164,958.42 | 28,093,493.13 |
| 财务费用 | 1,816,597.46 | 995,763.57 | 1,364,068.09 | 647,420.35 |
| 其中:利息费用 | 1,937,900.01 | 1,022,766.68 | 1,030,373.62 | 459,933.35 |
| 其中:利息收入 | 334,875.48 | 187,266.08 | 665,099.62 | 470,015.14 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 143,125 | -120,731.4 | 606,241.58 | 805,725.68 |
| 资产处置收益 | -5,569.63 | -3,159.53 | 32,334.57 | 1,470 |
| 资产减值损失(新) | -1,362,152.32 | -20,090.05 | -17,072,238.17 | 35,412.54 |
| 信用减值损失(新) | -374,075.42 | -1,227,677.9 | -7,443,414.67 | -6,460,317.84 |
| 其他收益 | 966,649.78 | 463,223.77 | 9,579,849.74 | 8,901,376.79 |
| 四、营业利润 | 23,980,044.84 | 17,848,423.42 | 28,243,591.47 | 31,497,237.71 |
| 加:营业外收入 | 885,978.75 | 1,320,317.23 | 23,603.65 | 11,592.96 |
| 减:营业外支出 | 80,331.55 | 62,127.92 | 247,916.82 | 174,832.72 |
| 五、利润总额 | 24,785,692.04 | 19,106,612.73 | 28,019,278.3 | 31,333,997.95 |
| 减:所得税费用 | 8,272,801.87 | 4,378,826.18 | 11,411,784.85 | 10,675,074.65 |
| 六、净利润 | 16,512,890.17 | 14,727,786.55 | 16,607,493.45 | 20,658,923.3 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 16,512,890.07 | 14,727,786.55 | 16,607,493.45 | 20,658,923.3 |
| 终止经营净利润 | 0.1 | - | - | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 20,404,091.44 | 14,866,096.67 | 27,416,909.65 | 27,836,338.53 |
| 少数股东损益 | -3,891,201.27 | -138,310.12 | -10,809,416.2 | -7,177,415.23 |
| 扣除非经常损益后的净利润 | 19,803,890.16 | 13,865,743.31 | 19,714,325.01 | 20,234,976.27 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.08 | 0.06 | 0.1 | 0.1 |
| (二)稀释每股收益 | 0.08 | 0.06 | 0.1 | 0.1 |
| 八、其他综合收益 | -75,889.46 | -16,948.91 | 74,362.59 | -112,095.04 |
| 归属于母公司股东的其他综合收益 | -75,889.46 | -16,948.91 | 74,362.59 | -112,095.04 |
| 九、综合收益总额 | 16,437,000.71 | 14,710,837.64 | 16,681,856.04 | 20,546,828.26 |
| 归属于母公司股东的综合收益总额 | 20,328,201.98 | 14,849,147.76 | 27,491,272.24 | 27,724,243.49 |
| 归属于少数股东的综合收益总额 | -3,891,201.27 | -138,310.12 | -10,809,416.2 | -7,177,415.23 |
| 公告日期 | 2025-08-28 | 2025-04-23 | 2025-04-23 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |